| 摘要: |
| 天然产物及其衍生物是药物的重要来源。Carfilzomib是一个以天然产物为先导通过结构优化得到的用于治疗多发性骨髓瘤的药物,其先导化合物Epoxomicin是从微生物中发现的具有抗癌活性的环氧酮肽类天然产物,能够选择性地抑制蛋白酶体,其环氧酮结构以独特的两步反应和蛋白酶体共价结合,因此克服了同类药物的脱靶缺点。以Epoxomicin为先导,通过结构优化得到活性更强、成药性性更好的Carfilzomib,作为新一代蛋白酶体抑制剂于2012年上市。 |
| 关键词: 蛋白酶体抑制剂 Carfilzomib Epoxomicin |
| DOI:10.13506/j.cnki.jpr.2015.10.001 |
| 基金项目:国家自然科学基金面上项目(No.81473110) |
|
|
|
| Carfilzomib:from natural product to drug |
| NIU Jun-xing,XU Xing-yu,HU Li-hong |
| (Shanghai Research Center for Modernization of Traditional Chinese Medicine,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China) |
| Abstract: |
| Natural products and their derivatives have been invaluable as a source of therapeutic agents.Carfilzomib,a potential chemotherapy drug for patients with multiple myeloma, was developed from a microbial natural product Epoxomicin.Epoxomicin was found to exhibit potent anti-cancer activity,which might attribute to its inhibitory activity against proteasome. Because of its unique two-step binding mode, Epoxomicin has a clear advantage compared to other proteasome inhibitors with their substantial off-target activity.With a more pontecy and better drug-like properties,Carfilzomib was developed from the lead compound Epoxomicin and approved by FDA as a second-generation proteasome inhibitor in 2012. |
| Key words: Proteasome inhibitor Carfilzomib Epoxomicin |